| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.27B | +4.4% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -67.2% |
| Gross margin | 15.2% | Net margin 0.5% |
| Revenue Q/Q | -4.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.23B | 84.8% |
| R&D | ¥0.01B | 2.4% |
| SG&A | ¥0.03B | 10.1% |
| Tax & other | ¥0.00B | 0.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份 ・ 金陵体育 ・ 雷迪克 ・ 正海生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies